Group 1 - The core point of the announcement is the approval of adjustments to the 2025 restricted stock incentive plan, including changes to the list of recipients and the number of shares granted [2][12][13] - The second board meeting was held on September 16, 2025, with all nine directors present, and the meeting followed legal and regulatory procedures [2][3] - The board approved the adjustment of the incentive plan, reducing the number of recipients from 124 to 120 and the number of shares from 6.65 million to 6.36 million [12][13] Group 2 - The restricted stock grant date is set for September 16, 2025, with a total of 6.36 million shares granted to 120 recipients at a price of 19.77 yuan per share [18][19][26] - The adjustments were made due to some recipients voluntarily reducing or forfeiting their entitlements, ensuring the plan's smooth implementation [13][22] - The board's compensation and assessment committee confirmed that the adjustments comply with relevant regulations and will not materially affect the company's financial status or operating results [14][15][26]
山东威高血液净化制品股份有限公司第二届董事会第十五次会议决议公告